Status:
COMPLETED
Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Erosive Esophagitis
Eligibility:
All Genders
15-80 years
Phase:
PHASE4
Brief Summary
To investigate the impact of initial treatment duration (4-week versus 8-week)of Esomeprazole (40mg) on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic er...
Detailed Description
Patients: Patients between the ages of 15 and 80 years with clinical symptoms of acid regurgitation, heart burn, or feeling of acidity in the stomach, who have Los Angeles Grade A and B erosive esoph...
Eligibility Criteria
Inclusion
- patients between the ages of 15 and 80 years
- with clinical symptoms of acid regurgitation, heart burn, or feeling of acidity in the stomach,
- who have Los Angeles Grade A and B erosive esophagitis proven by endoscopy are recruited.
Exclusion
- coexistence of peptic ulcer or gastrointestinal malignancies,
- pregnancy,
- coexistence of serious concomitant illness (for example, decompensated liver cirrhosis and uremia),
- previous gastric surgery,
- allergy to esomeprazole,
- symptom score of a validated questionnaire (Chinese GERDQ) less than 12, and
- equivocal endoscopic diagnosis of Los Angeles Grade A and B erosive esophagitis.
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
408 Patients enrolled
Trial Details
Trial ID
NCT01874535
Start Date
June 1 2010
End Date
June 1 2016
Last Update
September 4 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seng-Kee Chuah
Kaohsiung City, Taiwan, 833